Die besten 26’922 Jobs in der Region.
Job-typ
10-100%
Pensum
Position

24.11.2021

Operations Assistant (60%), Schweiz

  • 8952CH-8952 Schlieren
  • Festanstellung 60%

  • Merken
  • drucken

nSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Founded in 2009, the company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSightTM Microtissues including models derived from liver, pancreas, tumor, heart,brain, and skin. Microtissues are delivered directly to customers, or are accessible through 3D InSightTM Standard Services, where InSphero scientists conduct tailored screening projects with rapid turnaround and strict confidentiality.

 Supported by an unrivalled portfolio of 3D-optimized culture media, assay protocols, and imaging solutions, InSphero microtissues and services help to identify promising drugs and toxic liabilities with greater predictivity at early development stages. This enables better pre-clinical decision making, saves both development cost, and shortens time to market. Adopted by customers around the world, InSphero's panel of 3D InSight Microtissues display organotypic cell composition and morphology, greater longvity culture, and improved predictivity of compound efficacy and drug-induces toxicity compared to status quo 2-dimensional (monolayer) cell culture. Significant findings from research using InSphero's 3D microtissues continue to be published in peer-reviewed journals, and validated within the world's largest pharmaceutical companies and government institutions. Among the company's noteworthy ongoing collaborations are the EU Body on a Chip and HeCaTos projects, as well as a groundbreaking cancer screening initiative with the NIH's National Center for Advancing Translational Sciences (NCATS). InSphero's technology and know-how is now being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. The privately held company is headquartered in Schlieren close to Zurich, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. InSphero has been recognized for its scientific and commercial achievements with a number of national and international awards.
nSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Founded in 2009, the company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSightTM Microtissues including models derived from liver, pancreas, tumor, heart,brain, and skin. Microtissues are delivered directly to customers, or are accessible through 3D InSightTM Standard Services, where InSphero scientists conduct tailored screening projects with rapid turnaround and strict confidentiality.

 Supported by an unrivalled portfolio of 3D-optimized culture media, assay protocols, and imaging solutions, InSphero microtissues and services help to identify promising drugs and toxic liabilities with greater predictivity at early development stages. This enables better pre-clinical decision making, saves both development cost, and shortens time to market. Adopted by customers around the world, InSphero's panel of 3D InSight Microtissues display organotypic cell composition and morphology, greater longvity culture, and improved predictivity of compound efficacy and drug-induces toxicity compared to status quo 2-dimensional (monolayer) cell culture. Significant findings from research using InSphero's 3D microtissues continue to be published in peer-reviewed journals, and validated within the world's largest pharmaceutical companies and government institutions. Among the company's noteworthy ongoing collaborations are the EU Body on a Chip and HeCaTos projects, as well as a groundbreaking cancer screening initiative with the NIH's National Center for Advancing Translational Sciences (NCATS). InSphero's technology and know-how is now being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. The privately held company is headquartered in Schlieren close to Zurich, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. InSphero has been recognized for its scientific and commercial achievements with a number of national and international awards.
Laden...